focus -WSS

focus

author：focus 2025-10-02 00:41:12 - browse：28

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Future doctors need a strong humanities education

leisure time

hotspot

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Readout Newsletter: CAR

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Maisha Meds is a PBM, but don't call it that

Cardiologists urge adding sexual orientation, gender identity to health records

TikTok, Instagram influencers need more rules for drug ads

entertainment

focus

explore

Tori Bowie and the unacceptable rates of Black maternal death

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Prior authorization reform is both possible and imperative

Medicare details structure of new drug price negotiation program

Dana Farber says 6 studies to be retracted and 31 corrected

Medical records are filled with copy

Inaction leaves children at risk from dangerous chemotherapy drug

entertainment

Amid AI frenzy, a top HHS official's quest to create safeguards

Prior authorization reform is both possible and imperative

EPA limits use of carcinogenic gas for sterilizing medical devices

Flu vaccine reformulation won't be easy, manufacturers warn

Maisha Meds is a PBM, but don't call it that

Printout prescription drug information shouldn’t go digital

Wikipedia

leisure time

hotspot

leisure time